Evidence map›Paper›PMID 20927389›Full record

ArticlePloS one2010

Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation.

Riccardo Bernasconi, Tatiana Soldà, Carmela Galli, Thomas Pertel, Jeremy Luban, Maurizio Molinari

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Proline Isomerization as a Key Determinant for Hsp90-Toxin Interactions.Frontiers in cellular and infection microbiology · 2021
    Article
  7. CaBMC biology · 2020
    Article
  8. Protein quality control in the secretory pathway.The Journal of cell biology · 2019
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. ERAD and how viruses exploit it.Frontiers in microbiology · 2014
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Riccardo BernasconiInstitute for Research in Biomedicine, Bellinzona, Switzerland.
Tatiana Soldà
Carmela Galli
Thomas Pertel
Jeremy Luban
Maurizio Molinari
University of Geneva · CHÉcole Polytechnique Fédérale de Lausanne · CH

Funding

Cyclophilin A Function in the Immune SystemR01AI059159 · NIAID · UNIVERSITY OF GENEVA · PI LUBAN, JEREMY · 2006 to 2011
$1.4M
NIAID NIH HHS AI059159NIAID NIH HHS R01 AI059159
6 · The paper itself

Abstract

Peptidyl-prolyl cis/trans isomerases (PPIs) catalyze cis/trans isomerization of peptide bonds preceding proline residues. The involvement of PPI family members in protein refolding has been established in test tube experiments. Surprisingly, however, no data is available on the involvement of endoplasmic reticulum (ER)-resident members of the PPI family in protein folding, quality control or disposal in the living cell. Here we report that the immunosuppressive drug cyclosporine A (CsA) selectively inhibits the degradation of a subset of misfolded proteins generated in the ER. We identify cyclophilin B (CyPB) as the ER-resident target of CsA that catalytically enhances disposal from the ER of ERAD-L(S) substrates containing cis proline residues. Our manuscript presents the first evidence for enzymatic involvement of a PPI in protein quality control in the ER of living cells.

Indexed as

CyclophilinsCyclosporineDown-RegulationEndoplasmic ReticulumHeLa CellsHumansProtein Foldingcyclophilin BCyclophilinsCyclosporine

Identifiers

PMID20927389
PMCPMC2946916
OpenAlexW2024115241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.